GlycoMimetics, Inc. :GLYC-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017

GlycoMimetics, Inc. reports financial results for the year ended December 31, 2016.

We analyze the earnings along side the following peers of GlycoMimetics, Inc. – bluebird bio, Inc., Sanofi Sponsored ADR, Pfizer Inc., Palatin Technologies, Inc. and Johnson & Johnson (BLUE-US, SNY-US, PFE-US, PTN-US and JNJ-US) that have also reported for this period.

Highlights

  • Year-on-year change in operating cash flow of -260.73% is about the same as the change in earnings, likely no significant movement in accruals or reserves.
  • Earnings rose compared to same period last year, despite decline in operating and pretax margins.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

2016 2015 2014 2013 2012
Relevant Numbers (Annual)
Revenues 0.02 20.07 15.03 3.99 15.26
Revenue Growth (YOY) N/A N/A N/A N/A N/A
Earnings -31.81 -12.77 -11.12 -10.61 3.66
Earnings Growth (YOY) -149.11 -14.82 -4.87 -390.09 159.81
Net Margin -171945.07 -63.62 -74.01 -265.63 23.96
EPS -1.5 -0.67 -0.6 -0.57 0.2
Return on Equity -83.96 -27.98 -41.41 -137.42 34.84
Return on Assets -70.03 -24.16 -35.56 -89.49 15.45

Access our Ratings and Scores for GlycoMimetics, Inc.

Cash Versus Earnings – Sustainable Performance?

It is important to examine a company�s cash versus earnings numbers to gauge whether its performance is sustainable.

GLYC-US‘s change in operating cash flow of -260.73% compared to the same period last year is about the same as its change in earnings this period. Additionally, this change in operating cash flow is about average among its peer group. This suggests that the company did not use accruals or reserves to manage earnings this period, and that, all else being equal, the earnings number is sustainable.

Operating Cash Flow Growth Versus Earnings Growth

Quadrant label definitions. Hover to know more

Cash Flow based Earnings, Likely Non-cash Earnings, Low Cash Flow Base, Likely Undeclared Earnings

Margins

Despite a decline in operating (EBIT) margins as well as a decline in pretax margins, the company’s earnings rose.

EBIT Margin Versus PreTax Margin

Quadrant label definitions. Hover to know more

Operation driven Earnings, One-time Favorables, Low Earnings Base, One-time Unfavorables
EBIT Margin History
PreTax Margin History

Access our Ratings and Scores for GlycoMimetics, Inc.

Company Profile

GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani in April 2003 and is headquartered in Rockville, MD.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of GLYC-US.